MDMA for PTSD Under FDA Review; GLP-1 for Opioid Cravings; ADHD an Evolutionary Aid?

— News and commentary from the psychiatry world

MedicalToday
Illustration of a brain shaped maze.

The FDA is currently -- an MDMA-containing therapeutic -- as a potential post-traumatic stress disorder treatment to be used in combination with psychological intervention based on the phase III MAPP1 and MAPP2 studies, Lykos Therapeutics announced.

Is the DEA making the worse? (CBS News)

The GLP-1 medication liraglutide (Victoza, Saxenda) , according to a small study of 20 people with opioid use disorder. (STAT)

Areas of greater racial and ethnic diversity had significantly , with 45% to 55% fewer prescribers in urban areas and 62% to 79% fewer prescribers in rural areas as minority composition increased. (Journal of Addiction Medicine)

Hormone replacement therapy significantly in menopausal women when used either alone or as adjunct to antidepressants. (Menopause)

Was while foraging? (Proceedings of the Royal Society B: Biological Sciences)

A CDC study found that 6.4% of adults living alone -- higher than the 4.1% of those living with others.

Can affect offspring's brain development? A mouse study may provide clues. (Nature Communications)

Sleep signatures were altered after effective . (Translational Psychiatry)

More scientists and physicians are turning their attention to . (New York Times)

That being said, had a 6-fold higher mortality rate compared with males in the general population. (CMAJ)

Odor cues like the smell of ground coffee or tobacco ash evoked memories ; could they help with their therapy? (JAMA Network Open)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.